Loading
Every dated change on the records linked to Early triple-negative breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Primary DFS endpoint not met (figures not indexed); exploratory: avelumab benefit only with baseline TILs 30% or more (stratum B 3-year DDFS 92.
pCR 58% (48 to 67); RCB 0 or 1 69%; 3-year EFS 86% (98% with pCR, 68% without).
Germline-BRCA-wild-type cohort (Nature 2024): no pCR, EFS or OS improvement.
A milestone in how this cancer is treated.
Closed for futility: platinum not superior or non-inferior to capecitabine for iDFS in basal-like residual TNBC (primary hazard ratio not indexed).
iDFS HR 0.
5-year DFS 82.
A milestone in how this cancer is treated.
DFS HR 0.
Pathological complete response 58% vs 41% (all patients); 69% vs 49% in PD-L1-positive disease.
EFS HR 0.
A milestone in how this cancer is treated.
Carboplatin increased pathological complete response and improved disease-free survival in triple-negative breast cancer, without benefit in HER2-positive disease.
A milestone in how this cancer is treated.